WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to severe atopic dermatitis. The trial seeks to explore the safety, efficacy, and pharmacodynamics of ATI-2138 over a 12-week period with approximately 15 participants in the United States.
Dr. Neal Walker, Interim President & CEO of Aclaris, emphasized the significance of this milestone, stating, “We are thrilled to have dosed the first patient in this clinical trial, marking an important milestone for our ITK inhibitor programs.”
The study’s primary focus is on safety parameters, with secondary measures including EASI response scores and other efficacy indicators. Results are anticipated in the first half of 2025, potentially paving the way for new treatment options for atopic dermatitis patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.